These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
121 related articles for article (PubMed ID: 3802026)
21. Phase I study of alpha 2-interferon plus doxorubicin in patients with solid tumors. Sarosy GA; Brown TD; Von Hoff DD; Spiegel RJ; Golando JP; Beougher KL; Kuhn JG; Kisner DL Cancer Res; 1986 Oct; 46(10):5368-71. PubMed ID: 3756887 [TBL] [Abstract][Full Text] [Related]
22. Human lymphoblastoid interferon in the treatment of advanced epithelial ovarian malignancies: a Gynecologic Oncology Group Study. Abdulhay G; DiSaia PJ; Blessing JA; Creasman WT Am J Obstet Gynecol; 1985 Jun; 152(4):418-23. PubMed ID: 4040329 [TBL] [Abstract][Full Text] [Related]
24. Phase I trial of escalating dose doxorubicin administered concurrently with alpha 2-interferon. Green MD; Speyer JL; Hochster HS; Liebes LF; Dunleavy S; Widman T; Wernz JC; Blum RH; Spiegel RJ; Muggia FM Cancer Res; 1988 May; 48(9):2574-8. PubMed ID: 3356017 [TBL] [Abstract][Full Text] [Related]
25. Intraperitoneal alpha-interferon alternating with cisplatin in residual ovarian carcinoma: a phase II Gynecologic Oncology Group study. Berek JS; Markman M; Blessing JA; Kucera PR; Nelson BE; Anderson B; Hanjani P Gynecol Oncol; 1999 Jul; 74(1):48-52. PubMed ID: 10385550 [TBL] [Abstract][Full Text] [Related]
26. Phase I study of recombinant leukocyte A human interferon combined with BCNU in selected patients with advanced cancer. Creagan ET; Kovach JS; Long HJ; Richardson RL J Clin Oncol; 1986 Mar; 4(3):408-13. PubMed ID: 3950678 [TBL] [Abstract][Full Text] [Related]
28. Influence of interferon on the growth of primary ovarian carcinoma cells in a semi-solid agar system: comparison with clinical effects of interferon therapy. Ling P; Einhorn S; Anjegård IM; Brenning G; Einhorn N; Strander H Med Oncol Tumor Pharmacother; 1987; 4(2):81-6. PubMed ID: 3669781 [TBL] [Abstract][Full Text] [Related]
29. Interferon in the treatment of ovarian cancer. Welander CE Semin Oncol; 1988 Oct; 15(5 Suppl 5):26-9. PubMed ID: 2461594 [No Abstract] [Full Text] [Related]
30. Biological and clinical effects of the combination of beta- and gamma-interferons administered as a 5-day continuous infusion. Schiller JH; Storer B; Witt PL; Nelson B; Brown RR; Horisberger M; Grossberg S; Borden EC Cancer Res; 1990 Aug; 50(15):4588-94. PubMed ID: 2114942 [TBL] [Abstract][Full Text] [Related]
31. Combined intraperitoneal interferon alpha-2b and mitoxantrone in refractory ovarian cancer. Mäenpää J; Kivinen S; Räisänen I; Sipilä P; Väyrynen M; Gröhn P Ann Chir Gynaecol Suppl; 1994; 208():25-7. PubMed ID: 8092765 [TBL] [Abstract][Full Text] [Related]
32. [Interperitoneal alpha-2b interferon for advanced ovarian cancer in complete remission or minimal residual disease]. Cherchi PL; Dessole S; Esposito F; Ambrosini G; El Qandil FZ; Ambrosini A J Gynecol Obstet Biol Reprod (Paris); 1996; 25(1):101-2. PubMed ID: 8901311 [No Abstract] [Full Text] [Related]
33. Restoration of interferon alpha potentiation of a recombinant ricin A chain immunotoxin following cytoreduction of xenografts of advanced ovarian tumors. Pearson JW; Fogler WE; Volker K; Riggs CW; Gruys E; Groves ES; Wiltrout RH; Longo DL J Natl Cancer Inst; 1993 Jun; 85(11):907-12. PubMed ID: 8492319 [TBL] [Abstract][Full Text] [Related]
34. Alfa interferon: combinations with other antineoplastic modalities. Bonnem EM Semin Oncol; 1987 Jun; 14(2 Suppl 2):48-60. PubMed ID: 3296212 [TBL] [Abstract][Full Text] [Related]
36. Sequential combination of paclitaxel-carboplatin and paclitaxel-liposomal doxorubicin as a first-line treatment in patients with ovarian cancer. A multicenter phase II trial. Potamianou A; Androulakis N; Papakotoulas P; Toufexi H; Latoufis C; Kouroussis C; Christofilakis C; Xenidis N; Georgoulias V; Polyzos A Oncology; 2005; 69(4):348-53. PubMed ID: 16293974 [TBL] [Abstract][Full Text] [Related]
37. Intraperitoneal recombinant interferon gamma in ovarian cancer patients with residual disease at second-look laparotomy. Pujade-Lauraine E; Guastalla JP; Colombo N; Devillier P; François E; Fumoleau P; Monnier A; Nooy M; Mignot L; Bugat R; Marques C; Mousseau M; Netter G; Maloisel F; Larbaoui S; Brandely M J Clin Oncol; 1996 Feb; 14(2):343-50. PubMed ID: 8636742 [TBL] [Abstract][Full Text] [Related]
38. Phase II study of interferon alfa-2a, recombinant (Roferon-A) in metastatic renal cell carcinoma. Buzaid AC; Robertone A; Kisala C; Salmon SE J Clin Oncol; 1987 Jul; 5(7):1083-9. PubMed ID: 3598612 [TBL] [Abstract][Full Text] [Related]
39. Effects of alpha and gamma interferons and cytostatics on ovarian cancer in the subrenal capsule assay. Grönroos M; Mäenpää J; Söderström KO; Kangas L; Leppänen M; Cantell K Med Biol; 1983; 61(5):275-9. PubMed ID: 6200736 [TBL] [Abstract][Full Text] [Related]
40. In vitro drug testing of ovarian cancer using the human tumor colony-forming assay: comparison of in vitro response and clinical outcome. Federico M; Alberts DS; Garcia DJ; Emerson J; Fanta P; Liu R; Salmon SE Gynecol Oncol; 1994 Dec; 55(3 Pt 2):S156-63. PubMed ID: 7835801 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]